ABSTRACT BACKGROUND Diabetes mellitus causes microcirculatory rarefaction and may impair the responsiveness of ischemic
D
iabetes mellitus (DM) is one of the most important risk factors for developing cardiovascular disease (1, 2) . Moreover, DM induces additional major adverse coronary events after percutaneous coronary interventions (3-6) and bypass grafting, particularly if poorly controlled (7) . This comparative disadvantage is also evident when interventions are performed for acute coronary syndromes (8) and for chronic coronary lesions, aimed at resolving contractile dysfunction in viable myocardium (i.e., hibernating myocardium) (9, 10) .
Apparently, macrovascular treatment options for coronary obstructions are antagonized by additional factors beyond the reach of conventional recanalization strategies (11) .
A continuous inflammatory disposition of microvessels has been attributed to vessel regression in most organs (12) , except for reactive inflammatory vessel growth in the eye (13) . Both rarefaction and capillary sprouting imply vessel destabilization as a common denominator. In this concept, pericyte detachment is caused by inflammatory endothelial activation (13) . The diabetic inflammatory process might be aggravated by exogenous vessel-destabilizing factors such as vascular endothelial growth factor A (VEGF-A) (14) , potentially blunting its efficacy in therapeutic neovascularization. Enhancing microvascular stability (e.g., by providing platelet-derived growth factor B for pericyte attraction) has been demonstrated to increase blood flow into ischemic myocardium, when added to VEGF-A (15) . One vascular growth factor, which provides both capillary sprouting and pericyte investment, is thymosin beta 4 (Tb4) (16) , which induces lasting and functional microvascular networks in wild-type (wt) animals, and stabilizes microvessels in the instance of inflammation (17) .
To determine whether microvascular destabilization affects organ function and therapeutic neovascularization in a clinically relevant large animal model, we studied ischemic cardiomyopathy in INS C94Y transgenic pigs, a model of permanent neonatal DM (18) . In this model, fasting glucose levels increased to 300 to 400 mg/dl after birth. We analyzed hearts of 5-month-old db and wt pig hearts with or without hibernating myocardium, and applied regional adeno-associated virus (AAV)-based vascular gene therapy in the latter. Our results indicated that molecular treatment aiming at balanced vascular growth and maturation can improve hibernating myocardium in individuals with DM, although to a lesser extent than in age-matched non-DM controls. Myocardial tissue specimens were procured from patients undergoing heart transplantation (Online Recombinant AAV (rAAV) 2.9 vectors encoding b-galactosidase lacZ, Tb4, or VEGF-A were produced using the triple transfection method as described earlier (19) and in the Online Appendix.
METHODS
Transgenic pigs presenting with permanent neonatal DM were generated as described previously (18) . The INS C94Y mutation disrupts 1 of the 2 disulfide bonds between the A and B chains of the insulin molecule, resulting in misfolded insulin, impaired insulin secretion, endoplasmic reticulum stress, and apoptosis of the pancreatic beta cells. Consequently, these transgenic pigs present with permanent neonatal DM, which was treated with insulin until 7 days before experiment onset. Healthy nontransgenic littermates served as controls (Online Figure 1A) .
German landrace pigs were anesthetized and instrumented as previously described (20) heart slices compared to non-DM samples. Mean AE SEM; n ¼ 4; *p < 0.05. hpf ¼ high power field. 
RESULTS
Although db microvascular alterations are well known in peripheral or retinal tissue of patients, data are scarce that describe a structure-function correlation in db hearts. Therefore, we first compared myocardium of end-stage hearts from patients with and without DM undergoing heart transplantation, utilizing specimens of freshly explanted hearts for histological and functional analyses. We found a distinct capillary rarefaction and pericyte loss in hearts derived from patients with DM ( Figures 1A to 1C) , accompanied by a lowered angiopoietin (Ang) 1/Ang2 ratio in the DM group ( Figure 1D ). This microvascular alteration coincided with a loss of contractility in the papillary muscle ex vivo ( Figure 1E) . Moreover, wall stiffness, a parameter for impaired ventricular filling indicating diastolic heart failure, was found increased in the same hearts ( Figure 1F ), all confirming a correlation between microvascular disturbance and dysfunction in hearts from DM patients. Noteworthy, at 5 months of age with blood glucose levels >300 mg/dl ( Figure 3A) , a distinct capillary In a second set of experiments, we analyzed the response of db porcine hearts (blood glucose >300 mg/dl) ( Figure 4A ) and age-matched control hearts subjected to regional chronic ischemia inflicted by gradual occlusion of the circumflex artery. We found a higher degree of microcirculatory rarefaction in db than in normoglycemic hibernating myocardium (129 AE 7 c/hpf vs. 150 AE 4 c/hpf) ( Figures 4B and 4C ).
Pericyte investment of capillaries was also decreased in db hearts (106 AE 4 p/hpf vs. 136 AE 5 p/hpf) fibrosis in the ischemic tissue in both wt and db hearts. Mean AE SEM; n ¼ 6 to 8 for fibrosis. *p < 0.05; **p < 0.001. Abbreviations as in Figures 1, 3 , and 4.
( Figures 4B to 4D ). Of note, rAAV.Tb4 transduction significantly induced capillary growth and maturation in db pigs (183 AE 9 c/hpf, 163 AE 14 p/hpf), although it was less pronounced than in wt hearts (294 AE 6 c/hpf, 286 AE 7 p/hpf) ( Figures 4B to D) .
Treatment of db hearts with rAAV.VEGF-A treatment yielded an increase in capillaries (192 AE 4 c/hpf) ( Figures 4B and 4C) . However, the pericyte investment did not concomitantly increase (87 AE 4 p/hpf) ( Figures 4B and 4D ).
The number of collaterals, which may be formed to compensate for chronic total RCx occlusion, was low in both db and wt groups (2.1 AE 0.5 visible collaterals per heart vs. 1.9 AE 0.2 visible collaterals per heart) ( Figures 4E and 4F ). Upon rAAV.Tb4 transduction, however, collateral formation increased to a larger extent in wt hearts (6.7 AE 0.5 collaterals/heart) than in db hearts (4.7 AE 0.3 collaterals/heart) ( Figures 4E   and 4F ). Consistently, Rentrop score indicating distal filling of the occluded vessel reached a higher level in wt hearts than in db hearts (2.6 AE 0.2 vs.
2.1 AE 0.1) (Figures 4E and 4G) . vs. wt 16.7 AE 1.0%) ( Figure 5E ). In the ischemic region, recovery upon rAAV.Tb4 treatment was present in db hearts (8.5 AE 1.4% in treated db hearts vs. 1.9 AE 0.8% in untreated db hearts), but significantly less pronounced than in wt hearts (rAAV.Tb4 16.0 AE 1.2%) ( Figure 5F ). In the ischemic region of db hearts, rAAV.VEGF-A did not alter functional reserve (2.9 AE 0.7%) (Online Figure 2C) .
Because the complex myovascular interaction in db hearts destabilized microvessels and inhibited therapeutic vessel growth, we investigated the Ang1/Ang2 ratio in the ischemic hearts. The reduced Ang1/Ang2 ratio in ischemic tissue was enhanced upon Tb4 overexpression in wt as well as db hearts ( Figure 6A , Online Figure 1C ). However, rAAV.VEGF-A application did not improve the Ang1/Ang2 ratio, pointing to the lack of mature microvascular growth. In addition, we investigated the alterations in microribonucleic acid (miR), which might account for the pleiotropic actions induced by the hyperglycemic state. Three vasoactive miRs were found up-regulated in the hyperglycemic hearts (Online Figure 3) : miR 26a, which is implicated in impaired wound healing angiogenesis in DM (21); miR 92a, a known inhibitor of cardiac angiogenesis (22, 23) ; and miR 133a, whose level was previously reported to be elevated in db hearts (24) . We found these 3 miRs significantly up-regulated in the porcine db hearts (Online Figure 3) , suggesting them as potential novel mediators of microvascular rarefaction in DM. Diabetes mellitus impairs vascular density in the heart. Proangiogenic gene therapy via thymosin beta 4 (Tb4) or vascular endothelial growth factor-A (VEGF-A) induces capillary growth in the diabetic heart. However, only Tb4 is capable of inducing therapeutic neovascularization via vessel growth and maturation, thereby improving perfusion and myocardial function in ischemic normal as well as diabetic hearts. rAAV ¼ recombinant adeno-associated virus.
inflammatory destabilization of microvessels in sepsis (27) , but may also occur in chronic inflammatory endothelial activation (25) or in streptozotocininduced experimental DM (28) . Notably, increased
Ang2 expression has been found in aged db/db mice characterized by capillary rarefaction and fibrosis (29). In our study, the ratio of Ang1/Ang2 was slightly, but not significantly, decreased in db pig and human hearts compared to normoglycemic hearts ( Figures 1D and 6A, Online Figure 1C ), but increased upon rAAV.Tb4 treatment. In the human tissue, Tb4 expression was unaltered even though DM human corneas display a distinct Tb4 reduction (30) . However, the vascular growth induction by Tb4 was previously found to be sensitive to Ang2 (16) . Thus, an improved Ang1/Ang2 ratio appears crucial for the balanced vascular growth provided by rAAV.Tb4.
Interestingly, rAAV.VEGF-A had no effect on the Diabetes in CVD
